Colon cancer detection works because many cancers start as removable polyps.

Positive stool test: do not just repeat it

A positive FOBT/FIT or stool DNA-FIT generally needs diagnostic colonoscopy. Repeating the stool test until it becomes negative can miss intermittent bleeding and delays the examination that can biopsy cancer or remove polyps.

Which stool blood test is better?

For modern population screening, FIT is usually preferred over older guaiac FOBT. FIT is specific for human globin, needs fewer samples, does not usually require diet restrictions, can be quantitative, and lets programs adjust the positivity threshold to match colonoscopy capacity. Guaiac FOBT has the strongest older randomized-trial mortality evidence, but many countries replaced it with FIT because FIT is easier to use and performs better in practice.

Hard outcomes: stage III/IV disease, cancer-specific mortality and all-cause mortality

Test accuracy is only the beginning. The stronger evidence ladder is: fewer advanced cancers, fewer deaths from that cancer, and then fewer deaths overall. All-cause mortality is the hardest endpoint to move because colorectal cancer deaths are only a small fraction of all deaths in a screening-age population.

This is why a detection site should not only ask whether a test finds more abnormalities. It should ask whether those abnormalities are found early enough to change outcomes without too much overdiagnosis, false reassurance, false alarm, cost or treatment harm.

Average-risk and asymptomatic: FIT-first is often the saner default

For someone with no symptoms, no iron-deficiency anemia, no strong family history, no high-risk genetics and no prior significant polyps, the case for immediate colonoscopy is less clear than the case for doing regular FIT properly. Colonoscopy is more invasive, more expensive and more dependent on prep and endoscopist quality. FIT is cheaper, repeatable and scalable; the key is that a positive result must be followed by timely colonoscopy, not repeated until it becomes negative.

That does not make screening colonoscopy irrational. Some people reasonably prefer the one-test-plus-polyp-removal approach, and in countries such as the United States it remains an accepted option. But for public health systems and many average-risk individuals, a FIT-first program can be the better balance: reserve colonoscopy capacity for positive tests, symptoms, anemia, high-risk family/genetic settings and surveillance after important polyps.

A simple rule for each detection site

Population screening needs outcome evidence: fewer deaths, fewer advanced cancers, fewer preventable complications, or clearly better quality of life. Individual testing can reasonably tolerate more uncertainty if the person understands the chance of false alarms, missed disease, out-of-pocket costs and downstream procedures. The ethical mistake is selling uncertainty as reassurance.

A removed polyp is prevention you can hold in a pot

After colonoscopic removal, a polyp may look like a fleshy, bleeding lump rather than a neat textbook diagram. The important questions are whether it was removed completely, whether it was retrieved, whether removal was en bloc or piecemeal, its size and location, and what histology shows. Many colorectal cancers begin in adenomas or serrated lesions, so removing significant polyps early is the part of colonoscopy that can prevent cancer rather than merely detect it.

Follow-up depends on the worst polyp, the number of polyps, size and confidence of removal

Surveillance intervals below are broad, patient-facing examples from modern post-polypectomy guidance, especially US Multi-Society Task Force style intervals. Guidelines differ between countries and health systems, and this is not personal medical advice. Always ask your clinician what interval applies to your actual colonoscopy report, pathology report, bowel prep quality, family history and symptoms.

These examples assume a high-quality complete colonoscopy, adequate bowel prep, cecal intubation, complete removal and a patient without inflammatory bowel disease, hereditary syndrome or previous colorectal cancer. Poor prep, piecemeal removal, uncertainty about margins, strong family history or many polyps can shorten the interval.

The trend matters: for many low-risk findings the recommended interval has become longer, often 5, 7 or 10 years rather than reflexively 3. The exception is when the first exam was compromised, the lesion was large or piecemeal, dysplasia was advanced, there were many polyps, or the pathology suggests a higher-risk serrated or villous pathway.

FIT/FOBT sits beside this, not above it. If a person is returned to routine population screening after a normal or low-risk colonoscopy, they may resume annual FIT in some US-style pathways or biennial FIT in organized programs such as Australia or the NHS. But a negative FIT should not be used to postpone a surveillance colonoscopy that is due because of high-risk adenomas, advanced serrated lesions, piecemeal removal, poor prep or symptoms. A positive FIT/FOBT after any prior scope still needs proper clinical review and usually colonoscopy.

Frailty changes the value of finding a lesion

For an older or frail person who cannot tolerate colonoscopy, CT colonography may answer an important question with less procedural burden. But detection is only useful if the result can lead to a benefit the person could actually live to enjoy: safer endoscopic treatment, elective surgery, stenting, radiotherapy, symptom relief, palliative planning or a decision not to intervene. Finding a cancer in someone unlikely to survive colectomy or chemotherapy may create anxiety and procedures without improving life.